Kiwi Wealth Investments Limited Partnership Vertex Pharmaceuticals Inc Transaction History

Kiwi Wealth Investments Limited Partnership

$126 Million
Q4 2023

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$234.96 - $292.55 $3.22 Million - $4.01 Million	-13,697 Closed	0 $0
Q1 2022 May 17, 2022	BUY	$221.42 - $260.97 $3.03 Million - $3.57 Million	13,697 New	13,697 $3.58 Million
Q3 2021 Nov 16, 2021	SELL	$181.39 - $202.99 $5 Million - $5.6 Million	-27,581 Closed	0 $0
Q2 2021 Aug 17, 2021	BUY	$187.49 - $221.1 $233,425 - $275,269	1,245 Added 4.73%	27,581 $5.56 Million
Q1 2021 May 18, 2021	BUY	$207.02 - $241.31 $595,389 - $694,007	2,876 Added 12.26%	26,336 $5.66 Million
Q4 2020 Feb 17, 2021	BUY	$207.01 - $276.09 $4.34 Million - $5.79 Million	20,988 Added 849.03%	23,460 $5.55 Million
Q2 2020 Aug 14, 2020	SELL	$225.48 - $295.8 $735,966 - $965,491	-3,264 Reduced 56.9%	2,472 $718,000
Q4 2019 Feb 12, 2020	SELL	$166.71 - $223.91 $870,893 - $1.17 Million	-5,224 Reduced 47.66%	5,736 $1.26 Million
Q2 2019 Aug 14, 2019	BUY	$164.61 - $190.37 $1.8 Million - $2.09 Million	10,960 New	10,960 $2.01 Million

Others Institutions Holding VRTX

# of Institutions

1,723

Shares Held

222M

Call Options Held

1.58M

Put Options Held

1.36M

Capital World Investors Los Angeles, CA

26.8M
Shares

$12.1 Billion
1.99% of portfolio
Vanguard Group Inc Valley Forge, PA

23.2M
Shares

$10.4 Billion
0.2% of portfolio
Black Rock Inc. New York, NY

21.3M
Shares

$9.61 Billion
0.23% of portfolio
State Street Corp Boston, MA

11.8M
Shares

$5.33 Billion
0.23% of portfolio
Capital Research Global Investors Los Angeles, CA

9M
Shares

$4.06 Billion
0.9% of portfolio

View Full List

About VERTEX PHARMACEUTICALS INC

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $116B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

More about VRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Kiwi Wealth Investments Limited Partnership, based on Form 13F filings with the SEC.

News

Stay updated on Kiwi Wealth Investments Limited Partnership with notifications on news.

Account